

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/017766 A1

(51) International Patent Classification⁷: **A23L 1/302**,
C07D 495/04, A61K 31/16, 31/385, 31/045, 31/78, A23L
1/30

46, CH-4053 Basel (CH). **WEBER, Peter** [DE/DE]; Im
Grundacker 10, 79429 Malsburg-Marzell (DE).

(21) International Application Number:
PCT/EP2003/009112

(74) Agent: **MUELLER, Ingrid**; Wurmisweg 576, CH-4303
Kaiseraugst (CH).

(22) International Filing Date: 18 August 2003 (18.08.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02018847.0 23 August 2002 (23.08.2002) EP
03014625.2 26 June 2003 (26.06.2003) EP

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **DSM IP
ASSETS B.V.** [NL/NL]; Het Overloon 1, NL-6411 TE
Heerlen (NL).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **EGGERSDOR-
FER, Manfred, Ludwig** [DE/CH]; Muenchwilerstrasse
20, CH-4332 Stein (CH). **RAEDERSTORFF, Daniel**
[FR/FR]; 36c rue Bellevue, F-68350 Brunstatt (FR).
TEIXEIRA, Sandra, Renata [PT/CH]; Gempenstrasse

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: NOVEL NUTRACEUTICAL COMPOSITIONS COMPRISING BIOTIN

(57) Abstract: Abstract: Nutraceutical compositions comprise biotin in an amount sufficient to administer to a subject a daily dosage of 0.01 mg per kg body weight to about 3 mg per kg body weight and at least one additional component selected from pantethine or a metabolite thereof, EGCG, phytanic acid, lipoic acid and policosanol. The compositions are useful for the treatment of both type 1 and 2 diabetes, and for the prevention of type 2 diabetes in those individuals with pre-diabetes, or impaired glucose tolerance (IGT) or obesity.

WO 2004/017766 A1

Novel nutraceutical compositions comprising biotin

The present invention relates to novel nutraceutical compositions comprising biotin as the active ingredient for the treatment or prevention of diabetes mellitus, or other conditions associated with impaired glucose tolerance such as syndrome X and obesity, and at least one additional component selected from pantethine or a metabolite thereof, EGCG, phytanic acid, lipoic acid and policosanol. In one aspect the present invention relates to compositions comprising biotin in an amount sufficient to administer to a subject a daily dosage of 0.01 mg per kg body weight to about 3 mg per kg body weight, and at least one additional component selected from pantethine or a metabolite thereof, EGCG, phytanic acid, lipoic acid and policosanol, and to the use of such compositions as a nutritional supplement for the said treatment or prevention, e.g., as an additive to a multi-vitamin preparations comprising vitamins and minerals which are essential for the maintenance of normal metabolic function but are not synthesized in the body. In a further aspect, the present invention relates to such biotin compositions and their use wherein the additional component(s) is (are) selected from pantethine or a metabolite thereof, EGCG, phytanic acid and lipoic acid.

The compositions of the present invention are particularly intended for the treatment of both type 1 and 2 diabetes, and for the prevention of type 2 diabetes in those individuals with pre-diabetes, or impaired glucose tolerance (IGT), or obesity.

The compositions comprising a combination of active ingredients, i.e., biotin and at least one additional component selected from pantethine or a metabolite thereof, EGCG, phytanic acid, lipoic acid and policosanol have different mechanism of action on glucose metabolism and insulin sensitivity thus providing additive and/or synergetic effects in the treatment of diabetes.

- The term nutraceutical as used herein denotes a usefulness in both the nutritional and pharmaceutical field of application. Thus, the novel nutraceutical compositions can find use as supplement to food and beverages, and as pharmaceutical formulations for enteral or parenteral application which may be solid formulations such as capsules or tablets, or liquid formulations, such as solutions or suspensions. As will be evident from the foregoing, the term nutraceutical composition also comprises food and beverages containing biotin and at least one additional component selected from pantethine or a metabolite thereof, EGCG, phytanic acid, lipoic acid and policosanol, as well as supplement compositions containing the aforesaid active ingredients.
- Diabetes is a widespread chronic disease that hitherto has no cure. The incidence and prevalence of diabetes is increasing exponentially and it is among the most common metabolic disorder in developed and developing countries. Diabetes mellitus is a complex disease derived from multiple causative factors and characterized by impaired carbohydrate, protein and fat metabolism associated with a deficiency in insulin secretion and or insulin resistance. This results in elevated fasting and postprandial serum glucose that leads to complications if left untreated. There are two major categories of the diseases, insulin-dependent diabetes mellitus (IDDM, type 1) and non-insulin-dependent diabetes mellitus (NIDDM, type 2).
- Type 1 and type 2 diabetes are associated with hyperglycemia, hypercholesterolemia and hyperlipidemia. The insensitivity to insulin and absolute insulin deficiency in type 1 and 2 diabetes leads to a decrease in glucose utilization by the liver, muscle and the adipose tissue and to an increase in the blood glucose levels. Uncontrolled hyperglycemia is associated with increased and premature mortality due to an increased risk for microvascular and macrovascular diseases, including nephropathy, neuropathy, retinopathy, hypertension, stroke, and heart disease. Recent evidence showed that tight glycemic control is a major factor in the prevention of these complications in both type 1 and type 2 diabetes mellitus. Therefore, optimal glycemic control by drugs or therapeutic regimens is an important approach for the treatment of diabetes.
- Therapy of type 2 diabetes initially involves dietary and lifestyle changes, when these measures fail to maintain adequate glycemic control the patients are treated with oral hypoglycemic agents and/or exogenous insulin. The current oral pharmacological agents for the treatment of type 2 diabetes mellitus include those that potentiate insulin secretion (sulphonylurea agents), those that improve the action of insulin in the liver (biguanide agents), insulin sensitizing agents (thiazolidinediones) and agents which act to inhibit the uptake of glucose (α -glucosidase inhibitors). However, currently available agents generally

fail to maintain adequate glycemic control in the long term due to progressive deterioration in hyperglycaemia, resulting from progressive loss of pancreatic cell function. The proportion of patients able to maintain target glycemic levels decreases markedly overtime necessitating the administration of additional/alternative
5 pharmacological agents. Furthermore, the drugs may have unwanted side effects and are associated with high primary and secondary failure rates. Finally, the use of hypoglycemic drugs may be effective in controlling blood glucose levels, but may not prevent all the complications of diabetes. Thus, current methods of treatment for all types of diabetes mellitus fail to achieve the ideals of normoglycemia and the prevention of diabetic
10 complications.

Therefore, although the therapies of choice in the treatment of type 1 and type 2 diabetes are based essentially on the administration of insulin and of oral hypoglycemic drugs, there is a need for a safe and effective nutritional supplement with minimal side effects for the treatment and prevention of diabetes. Many patients are interested in alternative
15 therapies which could minimize the side effects associated with high-dose of drugs and yield additive clinical benefits. Patients with diabetes have a special interest in treatment considered as "natural" with mild anti-diabetic effects and without major side effects, which can be used as adjuvant treatment. Type 2 diabetes is a progressive and chronic disease, which usually is not recognized until significant damage has occurred to the
20 pancreatic cells responsible for producing insulin. Therefore, there is also an increasing interest in the development of a dietary supplement that may be used to prevent the development of diabetes in people at risk especially in elderly who are at high risk for developing diabetes. Furthermore, type 2 is a complicated disease resulting from coexisting defects at multiple organ sites: resistance to insulin action in muscle and adipose tissues,
25 defective pancreatic insulin secretion, unrestrained hepatic glucose production associated with lipid abnormalities and endothelial dysfunction. Therefore, given the multiple pathophysiological lesions in type 2 diabetes, combination therapy is an attractive approach to its management.

The use of biotin in daily dosages of about 0.01 mg per kg body weight to about 3 mg per
30 kg body weight, particularly in specific combinations with pantethine or a metabolite thereof, EGCG and/or phytanic acid which individually exert different mechanisms of action are effective in achieving and maintaining target blood glucose levels in diabetic patients.

The combinations of the active ingredients identified above are preferred because of their
35 different actions, to take advantage of additive/synergetic and multiorgan effects. Owing to

distinct mechanism of action of the individual active ingredients the combinations not only improve glycemic control, but also result in lower drug dosing in some settings and minimize adverse effects. Because of their distinct mechanism and sites of action, the specific combinations of dietary supplements discussed above also take advantage of
5 additive/synergetic effects to achieve a degree of glucose lowering greater than single agents can accomplish. Thus, although the therapies of choice in the therapeutic treatment of type 1 and type 2 diabetes is based essentially on the administration of insulin and of oral hypoglycemic drugs appropriate nutritional therapy is also of major importance for the successful treatment of diabetics.

10 The function of each of the active ingredients of the nutraceutical compositions of the present invention is described below:

Biotin: Biotin supplementation enhances hepatic glucose clearance which results in a decrease of circulating glucose concentration and induces decrease in the hepatic PEPCK activity. PEPCK is a rate-limiting cytosolic enzyme that catalyses the first committed step
15 of hepatic gluconeogenesis. Decrease of hepatic PEPCK activity results in a decrease in liver glucose output. In accordance with the invention it has been found that biotin given orally (2-16mg/day) or parentally (0.1mg/day) improved oral glucose tolerance in diabetic KK mice (NIDDM model), streptozotocin-diabetic rats (IDDM) and pre-diabetic Otsuka Long-Evans Tokushima fatty (OLETF) rats (NIDDM). Preliminary human studies showed
20 that after biotin supplementation fasting blood glucose levels decreased in type 1 and type 2 diabetic patients.

Thus, high doses of biotin may improve hyperglycemia in type 1 and type 2 diabetic patients. Biotin decreases hepatic glucose output and benefits glucose-stimulated insulin secretion. A combination of biotin with a product improving peripheral insulin sensitivity
25 is, therefore, valuable in diabetes management. Such products are, particularly, phytanic acid and lipoic acid.

EGCG: Epigallocatechin gallate (EGCG) is the major catechin found in green tea. In rats green tea catechins dose-dependently suppressed the increase in glucose and insulin levels in plasma after a starch or a sucrose rich meal. Combinations of biotin and EGCG
30 according to the invention are especially useful for patients who have impaired glucose tolerance, older patients who develop an increase in postprandial glucose due to aging, and patients with undiagnosed diabetes.

- Pantethine: In human studies oral administration of pantethine resulted in a progressive decrease in total cholesterol, triglycerides, low density lipoprotein (LDL) cholesterol and an increase in high density lipoprotein (HDL) cholesterol. Thus, resulting in a more favorable Chol/HDL ratio which reduces cardiovascular risk. Diabetes mellitus is associated with a 3- to 4-fold increase in risk of coronary artery disease. Type 2 diabetes mellitus adversely affects the plasma lipid profile, increasing levels of atherogenic lipids such as low density lipoproteins (LDL) and very low density lipoproteins (VLDL), but decreasing levels of high density lipoprotein (HDL), an antiatherogenic lipid. Atherosclerotic manifestations are not only common in individuals with diabetes but also result in significant long-term complications. Therefore, the oral supplementation with pantethine helps diabetes patients to normalize their lipid values reducing the risk of coronary heart disease and of thrombotic events. Instead of or in addition to panthethine, metabolites of pantethine such as cysteamine may find use in accordance with the invention.
- 15 Lipoic acid: Lipoic acid (1,2-dithiolane-3-pentaenoic acid) plays an essential role in mitochondrial-specific pathways that generate energy from glucose and may potentially influence the rate of glucose oxidation. Lipoic acid stimulates glucose transport in both muscle and adipose cells in culture. Moreover, administration of lipoic acid also raised basal and insulin-stimulated glucose uptake by skeletal muscles of glucose intolerant and non-insulin dependent diabetic animals. Furthermore, lipoic acid improves glucose disposal in patients with type 2 and may be incorporated in a nutraceutical composition of the present invention in order to prevent and/or treat the diabetic related complications and as agent with insulin sensitizing activity.
- 25 Phytanic acid: Phytanic acid (3, 7, 11, 15- tetramethylhexadecanoic acid) at concentrations ranging from about 10 to about 100 μ M enhances uptake of glucose in rat primary hepatocytes. Compared to the specific PPAR- γ agonist such as ciglitazone, phytanic acid exerts only minor effects on the differentiation of pre-adipocyte cells into mature adipocytes. Therefore, intake of phytanic acid helps to improve insulin sensitivity and may act as a preventative measure against type 2 diabetes and Syndrome X through activation of PPARs and RXR.
- 30 Policosanols: Policosanols is a mixture of primary aliphatic alcohols isolated and purified from plant waxes, mainly sugar cane. The aliphatic alcohol of the mixture is a $\text{CH}_3\text{-(CH}_2\text{)}_n\text{-CH}_2\text{OH}$ alcohol with chain length varying from 18 to 40 carbon atoms. Typical aliphatic alcohols of the mixture are octacosanol, hexacosanol, heptacosanol, triacontanol

and dotriacontanol. Policosanol has been shown to lower cholesterol in animal models, healthy volunteers, and patients with type II hypercholesterolemia. Therefore, it is useful in the dyslipidemia associated with type 2 diabetes mellitus.

- A multi-vitamin and mineral supplement may be added to the nutraceutical compositions of the present invention to obtain an adequate amount of an essential nutrient missing in some diets. The multi-vitamin and mineral supplement may also be useful for disease prevention and protection against nutritional losses and deficiencies due to lifestyle patterns and common inadequate dietary patterns sometimes observed in diabetes. Moreover, oxidant stress has been implicated in the development of insulin resistance.
- Reactive oxygen species may impair insulin stimulated glucose uptake by disturbing the insulin receptor signaling cascade. The control of oxidant stress with antioxidants such as α -tocopherol (vitamin E) ascorbic acid (vitamin C) may be of value in the treatment of diabetes. Therefore, the intake of multi-vitamin supplement may be added to the above mentioned active substances to maintain a good balanced nutrition.
- The nutraceutical composition of the present invention contains biotin in an amount sufficient to administer to a subject a dosage from about 0.01 mg to about 3 mg per kg body weight per day, preferably from about 0.1 mg to about 0.5 mg per kg body weight per day. Thus, if the nutraceutical composition is a food or beverage the amount of biotin contained therein is suitably in the range from about 0.03 mg per serving to about 50 mg per serving. If the nutraceutical composition is a pharmaceutical formulation such formulation may contain from about 0.35 mg to about 200 mg per solid dosage unit, e.g., per capsule or tablet, or a corresponding dosage in a liquid formulation, or from about 0.35 mg per daily dose to about 200 mg per daily dose.

- In a preferred aspect of the invention, the nutraceutical composition of the present invention further contains pantethine. The amount of pantethine in the composition may be such to provide a daily dosage from about 1 mg per kg body weight to about 50 mg per kg body weight of the subject to which it is to be administered. A food or beverage suitably contains about 20 mg per serving to about 800 mg per serving of pantethine. If the nutraceutical composition is a pharmaceutical formulation such formulation may contain pantethine in an amount from about 20 mg to about 1000 mg per dosage unit, e.g., per capsule or tablet, or from about 70 mg per daily dose to about 3500 mg per daily dose of a liquid formulation.

If EGCG is present in the composition according to the invention its amount may be such to provide a daily dosage from about 0.3 mg per kg body weight to about 30 mg per kg

body weight of the subject to which it is to be administered. A food or beverage suitably contains about 5 mg per serving to about 500 mg per serving of EGCG. If the nutraceutical composition is a pharmaceutical formulation such formulation may contain EGCG in an amount from about 10 mg to about 500 mg per dosage unit, e.g., per capsule or tablet, or
5 from about 20 mg per daily dose to about 2000 mg per daily dose of a liquid formulation.

If phytanic acid is present in the nutraceutical composition according to the invention its amount may be such to provide a daily dosage from about 1 mg per kg body weight to about 100 mg per kg body weight of the subject to which it is to be administered. A food or beverage suitably contains about 20 mg per serving to about 2000 mg per serving of
10 phytanic acid. If the nutraceutical composition is a pharmaceutical formulation such formulation may contain phytanic acid in an amount from about 30 mg to about 500 mg per dosage unit, e.g., per capsule or tablet, or from about 70 mg per daily dose to about 7000 mg per daily dose of a liquid formulation. Phytanic acid may also be used in the form of a biologically equivalent derivative thereof, such as an ester, e.g. the methyl or ethyl
15 ester.

If lipoic acid is present in the nutraceutical composition according to the invention its amount may be such to provide a daily dosage from about 0.3 mg per kg body weight to about 30 mg per kg body weight of the subject to which it is to be administered. A food or beverage suitably contains about 5 mg per serving to about 500 mg per serving of lipoic
20 acid. If the nutraceutical composition is a pharmaceutical formulation such formulation may contain lipoic acid in an amount from about 5 mg to about 800 mg per dosage unit, e.g., per capsule or tablet, or from about 5 mg per daily dose to about 2000 mg per daily dose of a liquid formulation.

If policosanol is present in the nutraceutical composition according to the invention its amount may be such to provide a daily dosage from about 0.002 mg per kg body weight to about 1.5 mg per kg body weight of the subject to which it is to be administered. A food or beverage suitably contains about 0.1 mg per serving to about 20 mg per serving of
25 policosanol. If the nutraceutical composition is a pharmaceutical formulation such formulation may contain policosanol in an amount from about 0.1 mg to about 30 mg per dosage unit, e.g., per capsule or tablet, or from about 0.1 mg per daily dose to about 100
30 mg per daily dose of a liquid formulation.

The nutraceutical compositions of the present invention preferably comprise combinations of

Biotin and pantethine. Also preferred are compositions comprising

Biotin and phytanic acid;

Biotin and EGCG;

Biotin and lipoic acid;

Biotin, phytanic acid and EGCG;

5 Biotin, phytanic acid and pantethine;

Biotin, pantethine and EGCG; and

Biotin, phytanic acid, pantethine and EGCG.

Dosage ranges (for a 70 kg person)

Biotin: 0.7 to 210 mg /day

10 EGCG: 20-2100 mg/day

Pantethine: 70-3500 mg/day

Phytanic acid: 70-7000 mg/day

Lipoic acid: 20-2100 mg/day

Policosanol: 0.15-100 mg/day

15 The following Examples illustrate the invention further.

A. Pharmaceutical compositions may be prepared by conventional formulation procedures using the ingredients specified below:

Example 1 : Soft gelatin capsule

20 Soft gelatin capsules are prepared by conventional procedures using ingredients specified below:

Active ingredients: Biotin 30 mg Pantethine 100 mg

Other ingredients: glycerol, water, gelatine, vegetable oil

Example 2: Hard gelatin capsule

25 Hard gelatin capsules are prepared by conventional procedures using ingredients specified below:

Active ingredients: Biotin 30 mg Pantethine 100 mg

Other ingredients:

Fillers: lactose or cellulose or cellulose derivatives q.s

Lubricant: magnesium stearate if necessary (0.5%)

Example 3: Tablet

Tablets are prepared by conventional procedures using ingredients specified below:

5 Active ingredients: Biotin 20 mg, pantethine 50 mg

Other ingredients: microcrystalline cellulose, silicone dioxide (SiO₂), magnesium stearate, croscarmellose sodium.

10 B. Food items may be prepared by conventional procedures using ingredients specified below:

Example 4: Soft Drink with 30% juice

Active ingredients:

15 Biotin and, optionally, one or more additional components selected from pantethine, EGCG, phytanic acid, lipoic acid and policosanol are incorporated in this food item

Biotin: 0.03-50 mg/ per serving

Pantethine: 20-800 mg/ per serving

EGCG: 5-500 mg/ per serving

Phytanic acid: 20-2000 mg/ per serving

20 Lipoic acid: 5-500 mg/ per serving

Policosanol: 0.1-20 mg/ per serving

Typical serving: 240 ml

I. A Soft Drink Compound is prepared from the following ingredients :

25 Juice concentrates and water soluble flavours

[g]

Orange concentrate

60.3 °Brix, 5.15% acidity 657.99

Lemon concentrate

30 43.5 °Brix, 32.7% acidity 95.96

Orange flavour, water soluble 13.43

- 10 -

Apricot flavour, water soluble	6.71
Water	26.46

1.2 Color

β-Carotene 10% CWS	0.89
5 Water	67.65

1.3 Acid and Antioxidant

Ascorbic acid	4.11
Citric acid anhydrous	0.69
10 Water	43.18

1.4 Stabilizers

Pectin	0.20
Sodium benzoate	2.74
Water	65.60

15 1.5 Oil soluble flavours

Orange flavour, oil soluble	0.34
Orange oil distilled	0.34

1.6 Active ingredients

20 Active ingredients (this means the active ingredient mentioned above: biotin and one or more of the following EGCG, pantethine, lipoic acid and/or phytanic acid) in the concentrations mentioned above.

Fruit juice concentrates and water soluble flavours are mixed without incorporation of air. The color is dissolved in deionized water. Ascorbic acid and citric acid is dissolved in water. Sodium benzoate is dissolved in water. The pectin is added under stirring and
25 dissolved while boiling. The solution is cooled down. Orange oil and oil soluble flavours are premixed. The active ingredients as mentioned under 1.6 are dry mixed and then stirred preferably into the fruit juice concentrate mixture (1.1).

In order to prepare the soft drink compound all parts 3.1.1 to 3.1.6 are mixed together before homogenising using a Turrax and then a high-pressure homogenizer ($p_1 = 200$ bar,
30 $p_2 = 50$ bar).

II. A Bottling Syrup is prepared from the following ingredients:

	[g]
Softdrink compound	74.50
Water	50.00
5 Sugar syrup 60° Brix	150.00

The ingredients of the bottling syrup are mixed together. The bottling syrup is diluted with water to 1 l of ready to drink beverage.

Variations :

- 10 Instead of using sodium benzoate, the beverage may be pasteurised. The beverage may also be carbonised.

Example 5 : 5 Cereal Bread

Active ingredients:

- 15 Biotin and one or more additional components selected from pantethine, EGCG, phytanic acid, lipoic acid and policosanol are incorporated in this food items

Biotin: 0.03-50 mg/ per serving

Pantethine: 20-800 mg/ per serving

EGCG: 5-500 mg/ per serving

Phytanic acid: 20-2000 mg/ per serving

- 20 Lipoic acid: 5-500 mg/ per serving

Policosanol: 0.1-20 mg/ per serving

Typical serving: 50 g

	[%]
5 cereal flour	56.8
25 Water	39.8
Yeast	2.3
Salt	1.1

The yeast is dissolved in a part of the water. All ingredients are mixed together to form a dough. Salt is added at the end of the kneading time. After fermentation, the dough is reworked and divided before a loaf is formed. Before baking, the surface of the loaf is brushed with water and sprinkled with flour.

5 Procedure parameters:

Kneading:

Spiral kneading system 4 min 1st gear; 5 min 2nd gear

Dough proofing: 60 min

Dough temperature: 22 - 24 °C

10 Proofing time: 30 min

Baking:

Oven: Dutch type oven

Baking temperature: 250/220 °C

Baking time: 50 - 60 min

15 Example 6: Cookies Type Milano

Active ingredients:

Biotin and one or more additional components selected from pantethine, EGCG, phytanic acid, lipoic acid and policosanol are incorporated in this food items

Biotin: 0.03-50 mg/ per serving

20 Pantethine: 20-800 mg/ per serving

EGCG: 5-500 mg/ per serving

Phytanic acid: 20-2000 mg/ per serving

Lipoic acid: 5-500 mg/ per serving

Policosanol: 0.1-20 mg/ per serving

25 Typical serving: 30 g

[g]

Wheat Flour, type 550 41.0

Sugar 20.5

Fat/Butter 20.5

30 Whole egg (liquid) 18.0

Lemon Flavour q.s.

Baking agent q.s.

All ingredients are added slowly under mixing to form a sweet short pastry.

Afterwards, the pastry is kept cool (4°C) for at least 2 hours before flattening the pastry to a thickness of approx. 5 mm. Pieces are cut out and brushed with egg yolk on the surface before baking.

5 Baking:

Oven:	fan oven
Baking temperature:	180 °C
Baking time:	15 min

10 Example 7 : Toast

Active ingredients:

Biotin and one or more additional components selected from pantethine, EGCG, phytanic acid, lipoic acid and policosanol are incorporated in this food items

Biotin: 0.03-50 mg/ per serving

15 Pantethine: 20-800 mg/ per serving

EGCG: 5-500 mg/ per serving

Phytanic acid: 20-2000 mg/ per serving

Lipoic acid: 5-500 mg/ per serving

Policosanol: 0.1-20 mg/ per serving

20 Typical serving: 100 g

	[%]
Wheat Flour, type 550	55.4
Water	33.2
Yeast	2.8
25 Salt	1.1
Fat/Butter	5.5
Malt	0.6
Emulsifier baking agent	1.4

The yeast is dissolved in a part of the water. All ingredients are mixed together to form a dough. Salt is added at the end of the kneading time. Afterwards, the dough is reworked, divided and placed in a baking tin for fermentation. After baking, the loaf is unmoulded directly.

5 Process parameters:

Kneading:

Spiral kneading system 5 - 6 min 1st gear; 3 - 4 min 2nd gear

- | | | |
|----|--------------------|------------|
| 10 | Dough proofing: | none |
| | Dough temperature: | 22 - 24 °C |
| | Proofing time: | 40 min |

Baking:

Oven: Dutch type oven

- 15 Baking temperature: 220 °C
 Baking time: 35 - 40 min

Example 8 : Yoghurt - set type, 3.5% fat

Active ingredients:

Biotin and one or more additional components selected from pantethine, EGCG, phytanic acid, lipoic acid and policosanol are incorporated in this food items

- 20 acid, lipoic acid and policosanol are incorporated in this food items

Biotin: 0.03-50 mg/ per serving

Pantethine: 20-800 mg/ per serving

EGCG: 5-500 mg/ per serving

Phytanic acid: 20-2000 mg/ per serving

- 25 Lipoic acid: 5-500 mg/ per serving

Policosanol: 0.1-20 mg/ per serving

Typical serving: 225 g

[%]

- | | | |
|----|--------------------------|------|
| | Full fat milk (3.8% fat) | 90.5 |
| 30 | Skimmed milk powder | 2.0 |

Sugar	5.0
Culture	2.5

The milk is heated to 35 °C before addition of milk powder, stabiliser, sugar and active ingredients. This mixture is heated to 65 °C to dissolve all ingredients. Then the mixture is
 5 homogenized in a high-pressure homogenizer ($p_1 = 150$ bar, $p_2 = 50$ bar) at 65 °C. This emulsion is then pasteurised at 80 °C for 20 minutes. After cooling to 45 °C natural yoghurt/culture is added and mixed. Then this mixture is filled into cups and fermented at 45 °C for 3-4 hours until a pH of 4.3 is reached and then stored at 4 °C.

Example 9: Yoghurt - stirred type, 3.5% fat

10 Biotin and, optionally, one or more additional components selected from pantethine, EGCG, phytanic acid, lipoic acid and policosanol are incorporated in this food items :

Biotin: 0.03-50 mg/ per serving

Pantethine: 20-800 mg/ per serving

EGCG: 5-500 mg/ per serving

15 Phytanic acid: 20-2000 mg/ per serving

Lipoic acid: 5-500 mg/ per serving

Policosanol: 0.1-20 mg/ per serving

Typical serving: 225 g

		[%]
20	Full fat milk (3.8% fat)	90.2
	Skimmed milk powder	2.0
	Stabiliser	0.3
	Sugar	5.0
	Culture	2.5

25

The milk is heated to 35 °C before addition of milk powder, stabiliser, sugar and active ingredients. This mixture is heated to 65 °C to dissolve all ingredients before homogenisation in a high-pressure homogenizer ($p_1 = 150$ bar, $p_2 = 50$ bar) at 65 °C. This emulsion is then pasteurised at 80 °C for 20 minutes. After cooling to 45 °C natural
 30 yoghurt/culture is added and mixed, followed by fermentation at 45 °C for 3-4 hours until a pH of 4.3 is reached. After cooling and stirring vigorously, the yoghurt is filled in cups and stored at 4 °C.

Example 10 : Ice cream, 8% fat

Active ingredients:

Biotin and one or more additional components selected from pantethine, EGCG, phytanic acid, lipoic acid and policosanol are incorporated in this food items

5 Biotin: 0.03-50 mg/ per serving

Pantethine: 20-800 mg/ per serving

EGCG: 5-500 mg/ per serving

Phytanic acid: 20-2000 mg/ per serving

Lipoic acid: 5-500 mg/ per serving

10 Policosanol: 0.1-20 mg/ per serving

Typical serving: 85 g

	[g]
Milk (3.7% fat)	600.00
Cream (35% fat)	166.00
15 Skim milk powder	49.10
Sugar	109.00
Glucose syrup 80%	70.00
Ice cream stabiliser	5.00
Flavor	q.s.

20 Colorq.s

Sugar, skim milk powder and stabiliser are added to the milk and cream, mixed and heated to 45 °C. Then the colour as stock solution and the glucose syrup is added as well as the active ingredients. The mix is heated up and pasteurized (20 min, 80 °C). Then a homogenization step takes place. Afterwards the mix is cooled down under constant stirring and the flavour is added at 5°C. The mix matured at 5 °C during at least 4 h and then passed through an the ice cream machine (overrun ca. 100%). The ice cream is filled into cups and stored at -20 to -30 °C.

25

Example 11 : Wine gums

Active ingredients:

Biotin and one or more additional components selected from pantethine, EGCG, phytanic acid, lipoic acid and policosanol are incorporated in this food items

5 Biotin: 0.03-50 mg/ per serving

Pantethine: 20-800 mg/ per serving

EGCG: 5-500 mg/ per serving

Phytanic acid: 20-2000 mg/ per serving

Lipoic acid: 5-500 mg/ per serving

10 Policosanol: 0.1-20 mg/ per serving

Typical serving: 30 g

	[g]
Gelatine 200 Bloom	80.0
Water I	125.0
15 Sugar crys.	290.0
Water II	120.0
Glucose-syrup DE 38	390.0
Citric acid	10.0
Flavour	2.0
20 Colour	q.s.
Yield ca	1000.0

Disperse gelatine in water I, stir and dissolve by heating over a steam bath or using a microwave. Mix sugar with water II and bring to boiling until a clear solution is obtained.

- 25 Remove from heat source. Mix with glucose syrup while dissolved sugar solution is still hot. Slowly add the gelatine solution. Let rest until foam on surface can be removed and 60-65°C is reached. Add flavour, citric acid and the colour solution as well as active ingredients under stirring. Deposit into moulds printed into starch trays and let sit for at least 48 hours at room temperature. Remove starch powder and polish with oil or wax. Dry
- 30 at room temperature and package into airtight pouches.

Example 12

The efficacy of the combination of biotin and phytanic acid as well as of both compounds alone on glucose removal was tested in a 5-week study in C57BLKS/J *db/db* mice (n=7-8/group). This model of late type 2 diabetes with severe hyperglycemia is widely used to determine the efficacy of anti-diabetic compounds.

Male *db/db* mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Adult mice aged 8 weeks were used in the experiment. Mice were housed individually in plastic cages with bedding and allowed free access to standard rodent food and tap water. The animal rooms were controlled for temperature (24°C), humidity (55%), and light (12-h light-dark cycle). The animals were randomized into four groups. Biotin and phytanic acid were administered as feed-ad-mix. Corn oil (1% of diet) served as a carrier substance for biotin and phytanic acid as well as a placebo when used alone. Group 1 received placebo, group 2 received biotin at a dose of 8 mg/kg body weight (BW)/day, group 3 received phytanic acid at a dose of 300 mg/kg BW/day, and group 4 received the combination of biotin and phytanic acid at a doses of 8 and 300 mg/kg BW/day, respectively. After 4 weeks of treatment glucose removal was assessed 90, 120, 150 and 180 minutes after an oral glucose load (1 g /kg body weight) . Blood samples were obtained 90, 120, 150, 180 minutes from the tail vein for determination of blood glucose levels.. Blood glucose was measured by a glucose analyzer (Glucotrend Premium, Roche Diagnostics, Rotkreuz, Switzerland). All data are expressed as means for animals in each diet group. Statistical significance of the mean differences between dietary groups was tested by one-way analysis of variance (ANOVA). If significant differences were found, the Dunnett's test for multiple comparison was used to compare each group to the control group. P values less than 0.05 were considered significant. All analyses were performed with Statistica (ver. 5.5A, StatSoft, Inc).

During the glucose load (1 g glucose/kg body weight) the blood glucose levels of animals treated with the combination of biotin and phytanic acid were lower at all time points when compared to the control group. Neither biotin nor phytanic acid caused a significant decrease in the glucose levels when used as a monotherapy.

The combined treatment with biotin and phytanic acid exerted an unexpected synergistic effect on the glucose removal rate (GRR). GRR is defined as the speed at which glucose is removed from blood and directed to the peripheral tissues. At 90, 120, 150 and 180 minutes after application of the glucose load blood glucose levels in animals treated with the combination of biotin and phytanic acid decreased to a greater extent than expected by the decrease due to monotherapy with biotin or phytanic acid. These facts indicate that GRR is synergistically enhanced in animals treated with the combination of biotin and

phytanic acid. To evaluate the GRR the glucose levels were expressed as the percent change of glucose levels for each group compared to the control group. Values of GRR are given in Table 1. The expected GRR is defined as the sum of the GRR exerted by biotin and by phytanic acid when used as a monotherapy.

5

Table 1

Glucose removal rate (% glucose decrease of control) at 90, 120, 150, and 180 minutes of an OGTT in *db/db* mice treated with biotin, phytanic acid, and the combination of both compounds.

	Glucose removal rate (%)			
	90 min	120 min	150 min	180 min
Biotin (8 mg/kg BW/day)	11.6	10.2	15.3	15.0
Phytanic acid (300 mg/kg BW/day)	9.7	12.5	14.6	15.2
Expected: (Biotin (8 mg/kg BW/day) + Phytanic acid (300 mg/kg BW/day))	21.3	22.7	29.9	30.2
Found: Biotin (8 mg/kg BW/day) + Phytanic acid (300 mg/kg BW/day)	25.9*	31.0*	35.1*	33.2*

* significantly different from control (p values less than 0.05)

- 10 Table 1 shows that the effect in the group supplemented with the combination of biotin and phytanic acid is greater than the sum of the effects of the groups receiving biotin and phytanic acid alone. Thus, the combination of biotin and phytanic acid has a synergetic effect on glucose metabolism.

Example 13

- 15 The effect of botin in combination with the compounds EGCG and cysteamine was investigated on the synergistic regulation of genes involved in liver glucose metabolism. The Affymetrix GeneChip® high-density oligonucleotide microarray approach was chosen to determine the global gene expression in H-4-II-E rat liver cells. Those genes that showed synergistic behaviour in their mode of regulation in one of the combination treatment
- 20 conditions were filtered out and glucose homeostasis marker genes were selected for further analysis. Liver carbohydrate metabolism is tightly regulated. Two specific enzymes, glucokinase (GK) and glucose-6 phosphatase (Glc6Pase), enable the liver to play a crucial role in glucose homeostasis. Since excessive production of glucose is the major cause of

fasting hyperglycemia and diabetes mellitus in humans, modulation of the hydrolysis of glucose-6-phosphate by Glc-6-Pase is the distal rate-determining enzymatic step in the process of releasing glucose into the circulation. A marked increase of hepatic Glc-6-Pase mRNA levels has been reported in diabetic animal models. Therefore compounds or
5 combinations of compounds that could reduce expression of the catalytic subunit of the Glc-6-Pase could be considered to normalize hyperglycemia and prevent the diabetic state. EGCG has previously been shown to decrease Glc-6-Pase mRNA levels in H-4-II-E cells. It is also known that biotin could induce the expression of GK in rat hepatocytes.

Cell culture

10 H-4-II-E rat liver cells were obtained from the American Type Culture Collection (ATCC) and cultured in Medium 199 (Invitrogen, Basel, Switzerland) supplemented with 10 % fetal calf serum in a humidified 5% CO₂ atmosphere at 37°C. Cells were regularly passaged at subconfluence and used at low passage numbers. For the final assays, cells were trypsinized, seeded at a density of 1 x 10⁶ cells/well in 6-well cell culture plates and
15 maintained in Medium 199 & 0.1% BSA (Invitrogen) for another 6h before compounds were applied. EGCG was applied in DMSO; cysteamine was first solved in 1M HCl and then applied to the stimulation medium, biotin was directly dissolved into the medium. After 24h treatment, total RNA was harvested.

High-density oligonucleotide array hybridization

20 A total number of 24 samples were prepared following the Affymetrix GeneChip® array protocol (Affymetrix, Santa Clara, Ca, USA). Briefly, total cellular RNA was extracted by using Qiagen RNeasy Mini Kit with an on-column RNase-free DNase I digest (Qiagen, Basel, Switzerland). A T7-(T)₂₄ primer (5'-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)₂₄-3') was annealed to 10µg of total RNA and
25 Superscript II reverse transcriptase (400 U) was utilized to synthesize first-strand cDNA in the presence of DTT, dNTPs and 1x reaction buffer. Second strand synthesis was performed by adding *E. coli* DNA polymerase I (40 U), *E. coli* ligase (10 U) and RNase H (2 U) in a final reaction containing 1x second strand buffer in the presence of dNTPs. Finally strands were blunted using T4 DNA polymerase (10 U) (Superscript™ Microarray
30 Customized Kit, Invitrogen, Basel, CH). cDNA was purified by phenol/chloroform extraction and subsequently *in vitro* transcription was carried out for 3h using T7 RNA polymerase (Megascript™ T7 Kit, Ambion, Texas, USA), incorporating bio-16-UTPs and bio-11-CTPs (Roche Molecular Biochemicals, Penzberg, Germany). After RNeasy purification, 10µg of the resulting cRNA was fragmented using 40mM Tris acetate (pH
35 8.1), 100 mM potassium acetate and 30mM magnesium acetate at 95°C for 35 min. A

hybridization cocktail was prepared containing 100mM MES buffer, 1M NaCl, 20mM EDTA, 0.01% Tween 20, the sample cRNA, fragmented bacterial control spikes, the biotinylated oligo 984, herring sperm DNA (0.5 µg/ µl; Invitrogen) and acetylated BSA (0.25 µg/µl; Promega, Madison, WI, USA) as described in the Affymetrix GeneChip®
 5 Expression Analysis Technical Manual. Samples were then hybridized onto Affymetrix Genechip® Rat 230 (SubA) for 16h at 45°C. Finally arrays were washed in the GeneChip® Fluidics 400 station (Affymetrix) with the EukGE-WS2v3 program and staining was carried out twice with streptavidinR-phycoerythrin (SAPE) using an antibody amplification protocol.

10 Data analysis

Raw fluorescence data were collected by confocal laser scanning (Hewlett Packard, Palo Alto, Ca, USA) and analyzed with the Affymetrix Microarray Suite (MAS 4.0). Data processing was carried out using the RACE-A analysis tool (Roche, Basel, Switzerland). All arrays were normalized against the mean of the total sums of Average Difference (AvgDiff)
 15 values across all used arrays. Normalized AvgDiff values below 4 were automatically assigned to a value of 4. Mean average difference values (MeanAvgDiff) and standard deviations (SD) were calculated from the replicate samples. Treatment groups were vehicle (V; 0.1% DMSO); 50µM EGCG (A), 1µM biotin (B), 50µM cysteamine (C), applied as single compounds, as well as the combinations of EGCG/biotin (D), and cysteamine/biotin
 20 (E); each experiment was performed in triplicate. For a comprehensive analysis genes with a maximal synergistic factor (SF) > +/- 1, combined with a significance level in a unpaired t-test of p < 0.05 were filtered. Relative gene expression within a treatment group is equal to the mean average difference (MeanAvgDiff). As the experiment is done in replicate, the corresponding mean values are $\overline{X}, \overline{Y}, \overline{M}, \overline{V}$; where the vehicle-treated condition is V, single
 25 compounds are X or Y and the multiplexed combination is M. The synergetic factor (SF) is considered as the ratio between the vehicle subtracted multiplexed gene expression and the vehicle subtracted additive gene expression, hence $SF = \frac{\overline{M} - \overline{V}}{(\overline{X} - \overline{V}) + (\overline{Y} - \overline{V})}$.

Results

H-4-II-E rat liver cells were stimulated with either vehicle (0.1% DMSO), 50µM EGCG,
 30 1µM biotin, 50µM cysteamine, applied as single compounds, as well as the combinations of EGCG/biotin, and cysteamine/biotin for 24h. Total RNA samples were processed to cRNA probes and hybridized to Affymetrix rat 230 (SubA) arrays. Calculations of the raw fluorescence data was carried out in the Affymetrix MAS 4.0 program. The MeanAvgDiff expression levels, standard deviations (SD) and the values of the SF for the glucose-6-

phosphatase gene expression were picked from a filtered list of genes generated in the RACE-A program.

Table 2

Compound(s)	MeanAvgDiff (Mean Relative Expression)	SD	SF
V (Vehicle)	535.01	96.24	-
A (EGCG)	484.8	34.36	-
B (Biotin)	516.66	60.82	-
C (Cysteamine)	447.42	18.69	-
D (EGCG/Biotin)	332.46	87.21	2.95 *
E (Cysteamine/Biotin)	343.91	59.85	1.80 *

* $p < 0.05$ (unpaired student's t-test)

- 5 Gene expression levels of the catalytic subunit of glucose-6-phosphatase (Affymetrix Id: 1370725_a_at) were determined using the Affymetrix GeneChip method. Mean average differences (MeanAvgDiff) were calculated by pair-wise comparisons of replicate samples.

The activity of Glc6Pase, which enables the liver to produce glucose, is increased during short-term fasting, in agreement with the enhancement of liver gluconeogenesis. On the other hand, GK activity, which allows the liver to utilize glucose, is decreased during fasting. In the fed state, the mechanisms of short-term regulation of the activity of both enzymes takes place during the postprandial period. Overproduction of glucose by the liver is the major cause of fasting hyperglycemia in both insulin-dependent and non-insulin-dependent diabetes mellitus. The distal enzymatic step in the process of glucose output is catalyzed by the glucose-6-phosphatase complex. As can be seen from Table 2, H-4-II-E cells treated with either EGCG/biotin or cysteamine/biotin show a unexpected synergistic decrease in the messenger RNA of the catalytic subunit of glucose-6-phosphatase. Accordingly, the data of Table 2 show that biotin surprisingly acts in a synergistic manner with EGCG or the pantethine metabolite cysteamine in down-regulating the expression of one of the major glucose-metabolism rate-limiting enzymes in rat liver cells. Consequently, such a combination treatment will reduce the glucose output and will therefore reduce hyperglycemia and prevent diabetes.

What is claimed is :

1. A composition comprising biotin in an amount sufficient to administer to a subject a daily dosage of 0.01 mg per kg body weight to about 3 mg per kg body weight and at least one additional component selected from pantethine or a metabolite thereof, EGCG,
5 phytanic acid, lipoic acid and policosanol.
2. A composition as in claim 1 wherein biotin and at least one additional component selected from pantethine or a metabolite thereof, EGCG, phytanic acid and lipoic acid is present.
3. A composition as in claim 1 or 2 wherein pantethine is present.
- 10 4. A composition as in claim 3 containing pantethine in an amount sufficient to administer to a subject a daily dosage of 1 mg per kg body weight to about 50 mg per kg body weight.
5. A composition as in any one of claims 1-4 wherein EGCG is present.
6. A composition as in claim 5 containing EGCG in an amount sufficient to administer to
15 a subject a daily dosage of 0.3 mg per kg body weight to about 30 mg per kg body weight.
7. A composition as in any one of claims 1-6 wherein phytanic acid is present.
8. A composition as in claim 7 containing phytanic acid in an amount sufficient to administer to a subject a daily dosage of 1 mg per kg body weight to about 100 mg per kg body weight.
- 20 9. A composition as in any one of claims 1-8 wherein lipoic acid is present.
10. A composition as in claim 9 wherein lipoic acid is present in an amount sufficient to administer to a subject a daily dosage of 0.3 mg per kg body weight to about 30 mg per kg body weight.
11. A composition as in any one of claims 1-10 wherein policosanol is present.
- 25 12. A composition as in claim 11 wherein policosanol is present in an amount sufficient to administer to a subject a daily dosage of 0.002 mg per kg body weight to about 1.5 mg per kg body weight.
13. A composition as in any one of claims 1-12 which is in dosage unit form.
14. A composition as in claim 13 wherein the dosage unit form is a solid dosage unit form.

15. A composition as in claim 14 wherein the dosage unit form contains about 0.35 mg to about 200 mg of biotin.
16. A composition as in claim 13 wherein the dosage unit form is a liquid dosage unit form.
- 5 17. A composition as in claim 16 wherein the dosage unit form contains about 0.35 mg to about 200 mg of biotin per ml.
18. A composition as in any one of claims 1-12 which is a food or beverage or a supplement composition for a food or beverage.
19. A food or beverage comprising about 0.03 mg to about 50 mg of biotin per serving and
10 at least one additional component selected from pantethine or a metabolite thereof, EGCG, phytanic acid, lipoic acid and policosanol.
20. A food or beverage comprising about 0.03 mg to about 50 mg of biotin per serving and at least one additional component selected from pantethine or a metabolite thereof, EGCG, phytanic acid and lipoic acid.
- 15 21. The use of biotin and at least one additional component selected from pantethine or a metabolite thereof, EGCG, phytanic acid, lipoic acid and policosanol in the manufacture of a nutraceutical composition, said biotin being used in an amount sufficient to provide a daily dosage of 0.01 mg per kg body weight to about 3 mg per kg body weight.
22. The use of biotin and at least one additional component selected from pantethine or a
20 metabolite thereof, EGCG, phytanic acid and lipoic acid in the manufacture of a nutraceutical composition, said biotin being used in an amount sufficient to provide a daily dosage of 0.01 mg per kg body weight to about 3 mg per kg body weight.
23. The use as in any one of claims 19-22 wherein the nutraceutical composition is a food or beverage, or a supplement composition for food or beverage.
- 25 24. The use as in claim 23 wherein the nutraceutical composition is intended for the treatment of both type 1 and 2 diabetes, and for the prevention of type 2 diabetes in those individuals with pre-diabetes, or impaired glucose tolerance (IGT) or obesity.
25. The use as in claim 24 wherein the nutraceutical composition is a pharmaceutical
30 composition for the treatment of both type 1 and 2 diabetes, and for the prevention of type 2 diabetes in those individuals with pre-diabetes, or impaired glucose tolerance (IGT) or obesity.

26. A method for the treatment of both type 1 and 2 diabetes, and for the prevention of type 2 diabetes in those individuals with pre-diabetes, or impaired glucose tolerance (IGT) or obesity which comprises administering to a subject in need of such treatment biotin in a daily dosage of 0.01 mg per kg body weight to about 3 mg per kg body weight together
5 with at least one additional component selected from pantethine or a metabolite thereof, EGCG, phytanic acid, lipoic acid and policosanol.

27. A method for the treatment of both type 1 and 2 diabetes, and for the prevention of type 2 diabetes in those individuals with pre-diabetes, or impaired glucose tolerance (IGT) or obesity which comprises administering to a subject in need of such treatment biotin in a
10 daily dosage of 0.01 mg per kg body weight to about 3 mg per kg body weight together with at least one additional component selected from pantethine or a metabolite thereof, EGCG, phytanic acid and lipoic acid.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/09112

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A23L1/302 C07D495/04 A61K31/16 A61K31/385 A61K31/045
A61K31/78 A23L1/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, FSTA, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	WO 03 028747 A (MARTIN ROBERT ;HARRIS DENNIS H (US); GENERAL RONALD E (US)) 10 April 2003 (2003-04-10) page 3, line 6-11 page 4, line 6-8 page 8 claims 1,2,4 ---	1,2,9, 10, 13-15, 21,22, 26,27
P, X	WO 02 076436 A (MEIJER JAAP) 3 October 2002 (2002-10-03) page 3; table 1 page 4, line 14 -page 5, line 3 examples 1A,2A,3A,6A,7A --- -/--	1,2,9, 10,13, 14,21,22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

20 November 2003

Date of mailing of the international search report

12/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Couzy, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/09112

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 203 819 B1 (FINE STUART A) 20 March 2001 (2001-03-20) column 9, line 19 -column 10, line 56	1,2, 9-14, 18-27
A	column 8, line 62 -column 10, line 56 ---	3-8,15
X	US 6 103 756 A (GORSEK WAYNE F) 15 August 2000 (2000-08-15) column 1, line 8,64 claims 1,2; table 1	1,2,9-27
A	column 1-2 ---	3-8
X	WO 02 47493 A (AVENTIS PHARMA GMBH) 20 June 2002 (2002-06-20) page 29-33 page 35 claims 1,3	1,2,9-27
A	page 29-33 ---	3-8,15
X	US 5 976 568 A (RILEY PATRICIA A) 2 November 1999 (1999-11-02) column 6, line 63 -column 7, line 1 column 20, line 42 -column 21, line 20 claims 1,2	1,2,5, 9-14, 16-27
A	column 19-28 ---	3-8,15
X	US 6 291 533 B1 (FLEISCHNER ALBERT M) 18 September 2001 (2001-09-18) column 15; claims 13-16	1,2,5,9, 10,13, 14,18-23
A	column 2, line 33-36 column 5-24 ---	3,4,6-8, 17,24-27
X	US 5 922 704 A (BLAND JEFFREY) 13 July 1999 (1999-07-13) table 2	1,2,5,6, 9-14, 16-23
A	column 3-4 ---	3,4,7,8, 15,24-27
A	MCCARTY M F: "TOWARD PRACTICAL PREVENTION OF TYPE 2 DIABETES" MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 54, no. 5, May 2000 (2000-05), pages 786-793, XP001019681 ISSN: 0306-9877 page 789-790 ---	1-27
A	EP 1 177 789 A (ROCHE VITAMINS AG) 6 February 2002 (2002-02-06) paragraphs '0014!-'0017! ---	1-27
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/09112

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1999 MCCARTY MF: "High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type-II diabetes" Database accession no. PREV199900343017 XP002262310 abstract -----	1-27

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/09112

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 26-27 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/09112

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03028747	A	10-04-2003	WO 03028747 A1	10-04-2003
			US 2003068391 A1	10-04-2003
WO 02076436	A	03-10-2002	NL 1017707 C2	01-10-2002
			WO 02076436 A2	03-10-2002
US 6203819	B1	20-03-2001	US 5962030 A	05-10-1999
US 6103756	A	15-08-2000	NONE	
WO 0247493	A	20-06-2002	DE 10109798 A1	12-09-2002
			EP 1214893 A1	19-06-2002
			AU 2193402 A	24-06-2002
			WO 0247493 A2	20-06-2002
			EP 1355539 A2	29-10-2003
			US 2002146463 A1	10-10-2002
US 5976568	A	02-11-1999	NONE	
US 6291533	B1	18-09-2001	US 2003044473 A1	06-03-2003
			US 6503529 B1	07-01-2003
US 5922704	A	13-07-1999	NONE	
EP 1177789	A	06-02-2002	EP 1177789 A2	06-02-2002
			BR 0103209 A	26-03-2002
			CA 2353805 A1	04-02-2002
			CN 1365667 A	28-08-2002
			JP 2002104964 A	10-04-2002
			US 2002082298 A1	27-06-2002